by barry101 | May 5, 2022 | Press Releases
– Preliminary positive safety and efficacy data from second Phase 1 AML study validate advancement to Phase 1/2 of Annamycin in combination with Cytarabine – Preclinical animal research demonstrated a 68% increase in OS with Annamycin and Cytarabine...
by barry101 | May 4, 2022 | Press Releases
Global leader with a distinguished 30-year career in oncology, hematology, and academia with significant contributions in clinical developments in ovarian cancer, lung cancer, and leukemias and lymphomas Company continues to advance clinical development across...
by barry101 | Apr 21, 2022 | Press Releases
Investigational New Drug (IND) application clearance from FDA opens up potential for additional investigator funded and led clinical studies HOUSTON, April 21, 2022 — Moleculin Biotech, Inc., (Nasdaq: MBRX) (“Moleculin” or the “Company”),...
by barry101 | Apr 14, 2022 | Press Releases
Company reiterates commitment to solving some of the toughest challenges in highly resistant cancers and viruses and developing better treatments that can make a real impact in people’s lives HOUSTON, April 14, 2022 — Moleculin Biotech, Inc., (Nasdaq:...
by barry101 | Apr 11, 2022 | Press Releases
In the news release, Moleculin Announces Presentation of Positive Preclinical Annamycin Data at the AACR 2022 Annual Meeting, issued 08-Apr-2022 by Moleculin Biotech, Inc. over PR Newswire, we are advised by the company that the second paragraph following the details...
by barry101 | Apr 8, 2022 | Press Releases
Annamycin exhibited robust antitumor activity in experimental colorectal cancer liver and lung metastasis models Results support advancement of preclinical development toward initiating clinical studies in metastatic colorectal cancer patients HOUSTON, April 8, 2022...
